NASDAQ:ATNF 180 Life Sciences (ATNF) Stock Price, News & Analysis $0.93 -0.03 (-3.23%) Closing price 06/17/2025 03:57 PM EasternExtended Trading$0.96 +0.03 (+3.66%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About 180 Life Sciences Stock (NASDAQ:ATNF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 180 Life Sciences alerts:Sign Up Key Stats Today's Range$0.90▼$0.9650-Day Range$0.69▼$1.3352-Week Range$0.66▼$17.75Volume32,064 shsAverage Volume792,258 shsMarket Capitalization$5.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Read More… 180 Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreATNF MarketRank™: 180 Life Sciences scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for 180 Life Sciences. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share Ratio180 Life Sciences has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 180 Life Sciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.12% of the float of 180 Life Sciences has been sold short.Short Interest Ratio / Days to Cover180 Life Sciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 180 Life Sciences has recently decreased by 21.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield180 Life Sciences does not currently pay a dividend.Dividend Growth180 Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.12% of the float of 180 Life Sciences has been sold short.Short Interest Ratio / Days to Cover180 Life Sciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 180 Life Sciences has recently decreased by 21.26%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for 180 Life Sciences this week, compared to 0 articles on an average week.Search Interest1 people have searched for ATNF on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, 180 Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.17% of the stock of 180 Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 4.07% of the stock of 180 Life Sciences is held by institutions.Read more about 180 Life Sciences' insider trading history. Receive ATNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 180 Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNF Stock News HeadlinesWeiss Ratings Reaffirms "Sell (E+)" Rating for 180 Life Sciences (NASDAQ:ATNF)June 12, 2025 | americanbankingnews.com180 Life Sciences Earnings Estimates, EPS & Revenue | NASDAQ:ATNF | BenzingaApril 21, 2025 | benzinga.comBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most investors are still asleep… but not for long. Garrett Goggin’s latest research reveals how you can “front-run” the greatest investor alive by positioning in four small miners sitting on up to 100X potential upside. When this hits the news — it’ll be too late.June 18, 2025 | Golden Portfolio (Ad)180 Life Sciences Corp. modifies former CEO's exit termsFebruary 8, 2025 | msn.com180 Life Sciences prices $2.9M registered direct offering at $2.41 per shareDecember 29, 2024 | markets.businessinsider.com180 Life Sciences CFO Omar Jimenez ResignsDecember 19, 2024 | markets.businessinsider.com180 Life Sciences files to sell 1.9M shares of common stock for holdersNovember 16, 2024 | markets.businessinsider.com180 Life Sciences files for secondary offering of common stockNovember 16, 2024 | msn.comSee More Headlines ATNF Stock Analysis - Frequently Asked Questions How have ATNF shares performed this year? 180 Life Sciences' stock was trading at $1.82 at the beginning of the year. Since then, ATNF shares have decreased by 49.0% and is now trading at $0.9290. View the best growth stocks for 2025 here. How were 180 Life Sciences' earnings last quarter? 180 Life Sciences Corp. (NASDAQ:ATNF) posted its earnings results on Thursday, May, 15th. The company reported ($0.67) earnings per share (EPS) for the quarter. When did 180 Life Sciences' stock split? 180 Life Sciences shares reverse split on Wednesday, February 28th 2024. The 1-19 reverse split was announced on Wednesday, February 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of 180 Life Sciences? Shares of ATNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 180 Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that 180 Life Sciences investors own include Meta Platforms (META), NIO (NIO), Enterprise Products Partners (EPD), HubSpot (HUBS), Netflix (NFLX), Plug Power (PLUG). Company Calendar Last Earnings5/15/2025Today6/17/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATNF CIK1690080 Webwww.kblmerger.com Phone(650) 507-0669FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-147.32% Return on Assets-76.99% Debt Debt-to-Equity RatioN/A Current Ratio1.02 Quick Ratio1.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.91 per share Price / Book0.32Miscellaneous Outstanding Shares5,700,000Free Float5,685,000Market Cap$5.30 million OptionableNo Data Beta0.23 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ATNF) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredWhat 99% of investors are missing about Chinese AIChinese AI chatbot DeepSeek's release put the spotlight on AI and turned the tech world on its head. But 99...Weiss Ratings | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.